Scholars@Duke
Dale Jay Christensen

Dale Jay Christensen

Adjunct Associate Professor in the Department of Medicine
Medicine, Hematology
dale.christensen@duke.edu
Duke Box 3711, Durham, NC 27710
200 Bryan Research Building, Durham, NC 27710

Scholarly Works - Journal articles

Safety and Efficacy of Inhaled Natural Product Powders That Enhance Mucociliary Clearance.

Journal article AAPS PharmSciTech · May 15, 2026 Mucociliary clearance is the lung's primary defense against inhaled pathogens and particulates, requiring optimal airway surface liquid hydration, mucus rheology, and coordinated ciliary beating. Diseases and pollutants disrupt these processes through alte ... Full text Open Access Link to item Cite

Generation of a shelf-stable, broadly-reactive influenza vaccine formulated with TLR4, TLR7/8, or TLR9 stimulating adjuvants.

Journal article Vaccine · February 6, 2026 Vaccine distribution to undeveloped regions of the world is often hindered by the lack of efficient cold-chain networks. In this study, the thin-film freezing (TFF) process was used to freeze-dry next generation influenza vaccines for shelf-stable storage. ... Full text Link to item Cite

Pulmonary and neurobehavioral efficacies of AVR-48, a TLR4 modulator, in a preterm lamb model of bronchopulmonary dysplasia.

Journal article Respir Res · August 25, 2025 BACKGROUND: AVR-48 is a small molecule that modulates toll-like receptor 4 (TLR4) activity, changing macrophage phenotype from pro- to anti-inflammatory and increasing the anti-inflammatory cytokine IL-10. Treatment with AVR-48 via intraperitoneal injectio ... Full text Link to item Cite

SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia.

Journal article Br J Haematol · February 2019 Alteration in RNA splicing is implicated in carcinogenesis and progression. Mutations in spliceosome genes and alternative splicing of other genes have been noted in chronic lymphocytic leukaemia (CLL), a common B cell malignancy with heterogeneous outcome ... Full text Link to item Cite

SPX-101 Is a Novel Epithelial Sodium Channel-targeted Therapeutic for Cystic Fibrosis That Restores Mucus Transport.

Journal article Am J Respir Crit Care Med · September 15, 2017 RATIONALE: Cystic fibrosis (CF) lung disease is caused by the loss of function of the cystic fibrosis transmembrane conductance regulator (CFTR) combined with hyperactivation of the epithelial sodium channel (ENaC). In the lung, ENaC is responsible for mov ... Full text Open Access Link to item Cite